Trial · NCT07892833
Becotatug Vedotin in Combination With Immunotherapy and Multimodality Radiotherapy for Esophageal Squamous Cell Carcinoma in the Second-line or Later Setting
NCT07892833, Phase 2, Recruiting, The First Affiliated Hospital of Bengbu Medical University
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Becotatug Vedotin in Combination With Immunotherapy and Multimodality Radiotherapy for Esophageal Squamous Cell Carcinoma in the Second-line or Later Setting. Trials, record NCT07892833. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07892833
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Becotatug Vedotin in Combination With Immunotherapy and Multimodality Radiotherapy for Esophageal Squamous Cell Carcinoma in the Second-line or Later Setting
- NCT number
- NCT07892833
- Status
- Recruiting
- Phases
- Phase 2
- Enrollment
- 38 participants, estimated
- Lead sponsor
- The First Affiliated Hospital of Bengbu Medical University
- Conditions
- ESCC
- Interventions
- Becotatug vedotin (MRG003)
- First posted
- 2026-10-23
- Last updated
- 2026-10-23
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Objective Response Rate | up to 2years | ORR is defined as the proportion of subjects achieving confirmed Complete Response (CR) or Partial Response (PR) as assessed by the investigator according to RECIST v1.1 and iRECIST criteria. ORR analysis will be based on the Full Analysis Set (FAS). |
| Secondary | Disease Control Rate | up to 2years | defined as the proportion of subjects achieving confirmed Complete Response (CR), Partial Response (PR), or Stable Disease (SD) lasting for at least 6 weeks from the first dose, as assessed by the investigator according to RECIST v1.1 and iRECIST criteria. DCR will be estimated together with its exact 95% CI using the Clopper-Pearson method. |
| Secondary | Progression-Free Survival | up to 2years | Progression Free Survival (PFS)s defined as the timefom enrollmentto the firstoccurence of disease progression or death from any cause. For subjectswithout observedprogression or death, PFS willbe censored at the time of the lastvalid and adequate assessment.FS analysis wilbe based on the FAS. Themedian PFS and its 95% C wll be estimated using theKaplan- Meier method, and progression-free survival curves will be generated. |
| Secondary | Overall survival | up to 2years | Overall survival (OS) is defined as the time from the date of first dose of study treatment to the date of death from any cause. For subjects who are alive at the time of analysis or who are lost to follow-up, OS will be censored at the date of last known alive. Subjects with no post-baseline information will be censored at the date of first dose. OS will be estimated using the Kaplan-Meier method, and the median OS with its 95% CI will be calculated (with the 95% CI for the median derived using the Brookmeyer-Crowley method). |
| Secondary | Duration of relief | up to 2years | For patients who have confirmed remission (as evaluated by RECIST v1.1 and iRECIST criteria, with PR or CR status), the time period between the first evidence of remission (PR or CR) and the first evidence of disease progression (PD) or death due to any cause. For subjects who did not show progression or death, the DOR will be censored at the last time of adequate tumor assessment. |
| Secondary | Treatment Emergent Adverse Events (Safety and Tolerability） | From the first dose of study treatment through 30 days after the last dose of study treatment (up to 2 years) | Incidence of adverse events (AEs), serious adverse events (SAEs), treatment-related adverse events (TRAEs), and immune-related adverse events (irAEs); severity grading; and laboratory abnormalities, assessed according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 6.0. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07892833
GET https://conductscience.org/api/trials/v1/NCT07892833/registered